Clinical Trial Update: 18F ML-10 for Early Detection of Response of Brain Metastases to SRS [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for 18F-ML-10 to detect early response of brain metastases to SRS; the study sponsored by Aposense Ltd has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases of Unknown Primary

Drugs mentioned

• [18F]-ML-10 (Fluorine-18 ML-10)

Snippet

Sponsor: Aposense Ltd. | Conditions: Metastasis to Brain of Unknown Primary | Phase 2 | Status: TERMINATED